ADDF Diagnostics Accelerator Funding for FTD Biomarker Development
Forecasted
ADDF Diagnostics Accelerator Funding for FTD Biomarker Development supports researchers developing biomarkers for frontotemporal degeneration to advance diagnosis and treatment.
Funder: The Association for Frontotemporal Degeneration
Due Dates (Anticipated): January 2027 (Letter of Intent)
Funding Amounts: Close to $5 million provided to date for FTD biomarker development
Summary: AFTD and ADDF support frontotemporal degeneration biomarker development through ADDF’s Diagnostics Accelerator.
Description
The Association for Frontotemporal Degeneration (AFTD) partners with the Alzheimer’s Drug Discovery Foundation (ADDF) to support biomarker development for frontotemporal degeneration (FTD) through ADDF’s Diagnostics Accelerator (DxA). This funding is part of the organizations’ broader partnership to advance FTD diagnosis and treatment.
Launched in July 2018, the Diagnostics Accelerator operates within ADDF’s venture philanthropy strategy. This model provides flexibility to support promising, cutting-edge research even when an immediate commercial return is not guaranteed. It balances a willingness to take greater risks than traditional venture capital funds with a focus on the short-term development of products for the marketplace.
